Reducing length of stay after transfemoral transcatheter aortic valve implantation: the FAST-TAVI II trial
Eric Durand,Delphine Beziau-Gasnier,Morgane Michel,Bernard Iung,Didier Tchetche,Guillaume Bonnet,Thibault Lhermusier,Martine Gilard,Geraud Souteyrand,Claire Bouleti,Patrick Ohlmann,Thierry Lefevre,Farzin Beygui,Stephan Chassaing,Karine Chevreul,Hélène Eltchaninoff,Benjamin Alos,Marc-Antoine Arnould,Olivier Bar,Christophe Barbey,Bernard Bertrand,Farzin Beygui,Mathieu Bignon,Marine Bouchat,Frédéric Bouisset,Claire Bouleti,Fransisco Campelo-Parada,Stephan Chassaing,Nicolas Combaret,Nicole Darodes,Stéphane Delepine,Romain Didier,Bruno Dongay,Nicolas Dumonteil,David Fouassier,Romain Gallet de Saint Aurin,Martine Gilard,Guillaume Gouffran,Dominique Himbert,Louis Le Bivic,Thierry Lefèvre,Adrien Lemaitre,Lionel Leroux,Gilles Levy,Thibaut Lhermusier,Luc Lorgis,Jean-François Morelle,Patrick Ohlmann,Christophe Piot,Thibaut Pommier,Idir Rebouh,Vincent Roule,Dan Rusinaru,Géraud Souteyrand,Christian Spaulding,Didier Tchetche,Emmanuel Teiger,Christophe Tribouilloy,Hélène Eltchaninoff,Jérémy Bellien,Benjamin Bertrand,Farzin Beygui,Delphine Béziau-Gasnier,Ebba Brakenhielm,Giuseppina Caligiuri,Karine Chevreul,Frédérique Debroucker,Eric Durand,Christophe Fraschini,Martine Gilard,Bernard Iung,Said Kamel,Jamila Laschet,Alain Manrique,Emmanuel Messas,David Messika-Zeitoun,Florence Pinet,Vincent Richard,Eric Saloux,Martin Thoenes,Christophe Tribouilloy,Claire Vézier,FAST-TAVI II,STOP-AS investigators
DOI: https://doi.org/10.1093/eurheartj/ehae081
IF: 39.3
2024-03-05
European Heart Journal
Abstract:The length of stay (LOS) after transcatheter aortic valve implantation (TAVI) remains extremely variable whereas early discharge has been shown to be feasible and safe. The study objective was to evaluate the efficacy and safety of an intervention aimed at reducing LOS after transfemoral TAVI. FAST-TAVI II is a prospective, multicentre, cluster, randomized, controlled study including patients with severe symptomatic aortic stenosis, who had transfemoral TAVI. The intervention consisted in a dedicated training programme to implement 10 quality of care measures to reduce LOS with an implementation phase of eight weeks. The primary endpoint was the proportion of patients discharged early within 3 days. Secondary endpoints included: LOS, 30-day mortality and 30-day incidence of readmission for cardiovascular events. During the study period, 969 patients were enrolled in the intervention group and 860 patients in the control group. Mean age was 81.9 ± 6.6 years and mean EuroSCORE II was 4.4 ± 4.5%. Early discharge was achieved in 563 (58.1%) patients in the intervention group vs. 364 (42.3%) patients in the control group ( P < .0001). Median LOS was significantly reduced in the intervention group compared to the control group [3 (IQR: 3) vs. 4 days (IQR: 3), P < .0001]. Thirty-day mortality was low and similar in the two groups (0.5% vs. 0.9%, P = .30), as were 30-day readmissions (4.6% vs. 2.8%, P = .28). The intervention was simple and fast to implement, and was effective and safe to reduce LOS and increase the proportion of patients discharged early after TAVI (NCT04503655). This prospective, multicentre, cluster, randomized controlled study included patients with severe symptomatic aortic stenosis who had transfemoral transcatheter aortic valve implantation in 20 French centres. Ten centres were allocated to the intervention group, which consisted in a dedicated training programme including 10 quality of care measures to reduce length of stay with an implementation phase of eight weeks. The other 10 centres received no training and carried on as usual (control group). The proportion of patients discharged early was significantly higher in the intervention group than in the control group in the overall population as well as in patients who received a balloon or a self-expandable prosthesis.
cardiac & cardiovascular systems